Browse drugs

…fined. TM1 (n=325 genes) enrichment associated most highly with ustekinumab resistance (Spearman rank correlation, ρ: -0.26), along with TM…

…l surgery.Advanced therapies used for treatment of OFG included adalimumab (n=56), infliximab (n=52), ustekinumab (n=23), risankizumab (n=…

…erval (33.3%) and to restart the drug (25.0%). In patients with ustekinumab, the main interventions were to shorten the dosing interval (55…

…ent followed by another anti-TNFa treatment or Vedolizumab then Ustekinumab. Median age at diagnosis was 8 years. We found that (40%) switc…

…Objective To evaluate the effectiveness and safety of mirikizumab in patients with ulcerative colitis in clinical practice.Method…

…127) of the cohort, of which 12% (n=92) were serious.Conclusion Risankizumab was effective in a large, real-world, medically refractory CD c…

… receiving biologic therapy at the time of the audit, including infliximab in 47, adalimumab in 13, ustekinumab in 2, and vedolizumab in 1…

…revious cohort study of Crohn’s disease (CD) patients receiving ustekinumab (UST), our team observed that responders exhibited a significan…

…b 44.3%, Adalimumab 27.9%, Vedolizumab 13.1%, Ustekinumab 9.8%, Golimumab 3.3% and Risankizumab 1.6%.The mean [±SD] gestational age at tr…

…reported in icotrokinra treatment groups through W12.Conclusion Icotrokinra, the first-in-class targeted oral peptide that selectively bloc…

…ommon recent drugs were adalimumab, infliximab, ustekinumab and vedolizumab. There were no significant differences between groups in potent…

… ≥2, and inadequate response/intolerance (IR) to TNFa blockers, vedolizumab, ustekinumab, JAK inhibitors, or S1P receptor modulators (BIO/J…